1)5 794A

PTO/SB/01A (09-04)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
medicion		
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	E OF INVENTOR(S)	
Inventor on	e: DANIEL COHEN	
Signature:	Citizen of: FRANCE	
Inventor tw	o: ILYA CHUMAKOV 1946	
	Citizen of: FRANCE	
Inventor th	ree: MARTA BLUMENFELD	
Signature:	Citizen of: FRANCE	
Inventor for	ur: SANOBER SHAIKH	
Signature:	Citizen of: GREAT BRITAIN	
✓ Addi	tional inventors or a legal representative are being named on oneadditional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/519336

PTO/SB/01A (09-04) Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any a specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FID L MANA	OF INVENTORYO	
	E OF INVENTOR(S)	
	Citizen of: FRANCE	
Inventor six	: HADI ABDERRAHIM	
Signature: _	Citizen of: _FRANCE	
	ven: PASCALE GREL	
Signature:	Citizen of: _FRANCE	
Inventor eig	ht:	
Signature: _	Citizen of:	
Addit	onal inventors or a legal representative are being named onadditional form(s) attached hereto.	

US Jaux

Rec'd PCT/PTO 25 JUL 2005

10/519356
PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
Invention			
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
ļ	The attached application, or		
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAM	E OF INVENTOR(S)		
Inventor on	Inventor one: DANIEL COHEN		
Signature:	· Citizen of: FRANCE		
Inventor tw	Inventor two: ILYA CHUMAKOV		
Signature:	Citizen of: _FRANCE		
Inventor the	ree: MARTABLUMENEELD		
Signature:	Me3L S Citizen of: FRANCE —		
Inventor for	ur: SANOBER SHAIKH		
Signature:	Citizen of: GREAT BRITAIN		
✓ Addi	tional inventors or a legal representative are being named ononeadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declara	ation is directed to:	
	The attached application, or	
	Application No. <u>PCT/EP2003/050247</u> , filed on <u>JUNE 20, 2003</u> ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
	E OF INVENTOR(S)	
	e: MARTA PALICIO-BARRON	
Signature: _	Citizen of: FRANCE	
Inventor six	HADI ABDERRAHIM	
Signature:Citizen of: _FRANCE		
Inventor se	ven: PASCALE GREL	
Signature:	Citizen of: _FRANCE	
Inventor eig	ht:	
Signature:	Citizen of:	
Addit	onal inventors or a legal representative are being named on additional form(s) attached hereto.	

Rec'd PCT/PTO_25 JUL 2005) 5 4944 10/519356

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
	E OF INVENTOR(S)		
	e: DANIEL COHEN		
Signature:Citizen of: FRANCE			
Inventor two	Inventor two: ILYA CHUMAKOV		
Signature:	Citizen of: FRANCE		
Inventor thr	ee: MARTA BLUMENFELD		
Signature:	Citizen of: FRANCE		
_	Ir: SANOBER SHAIKH		
Signature:	Sitizen of: GREAT BRITAIN		
Addit	ional inventors or a legal representative are being named on One additional form(s) attached hereto.		

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declara	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any tapecifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
	E OF INVENTOR(S)	
	e: MARTA PALICIO-BARRON	
Signature: _	Signature:Citizen of: FRANCE	
Inventor six	: HADI ABDERRAHIM	
Signature:	gnature:Citizen of: FRANCE	
Inventor se	ven: PASCALE GREL	
Signature: _	Citizen of: FRANCE	
Inventor eig	ht:	
Signature: _	Signature:Citizen of:	
Addit	ional inventors or a legal representative are being named on additional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. PCT/EP2003/050247, filed on _JUNE 20, 2003,		
	as amended on (if applicable);		
I/we believe sought;	I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any specifically referred to above;		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
	E OF INVENTOR(S)		
Inventor one: _DANIEL COHEN Signature: Citizen of: FRANCE			
Signature.	Olizell VI. Transc		
Inventor two	D: ILYA CHUMAKOV		
Signature:	Citizen of: _FRANCE		
Inventor thr	ee: MARTA BLUMENFELD		
Signature: _	Citizen of: FRANCE		
Inventor fou	r:_SANOBER SHAIKH		
Signature: _	Citizen of: GREAT BRITAIN		
✓ Addit	onal inventors or a legal representative are being named on additional form(s) attached hereto.		

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

1. 20. 15 6 1 24

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatme	ent of Mental Disorders
As the belo	ow named inventor(s), I/we declare that:	
This declar	ration is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on _	It INE 20, 2003
	74phication 140. <u></u>	
	as amended on	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter	which is claimed and for which a patent is
	reviewed and understand the contents of the above-identified application nt specifically referred to above;	n, including the claims, as amended by any
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	E OF INVENTOR(S)	
nventor fiv	ve: MARTA PALICIO-BARRON.	
Signature:	MartaPalicas Citi	zen of: FRANCE
Inventor six	x: HADI ABDERRAHIM	
Signature:	Citi	zen of: FRANCE
Inventor se	even: PASCALE GREL	
Signature:	Citi	zen of: FRANCE
Inventor eight:		
Signature:	Citi	zen of:
Addi	itional inventors or a legal representative are being named on	additional form(s) attached hereto.
This collection (and by the U	not information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to JSPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFF inplete, including gathering, preparing, and submitting the completed application form to the	o obtain or retain a benefit by the public which is to file R 1.11 and 1.14. This collection is estimated to take 1

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any tapecifically referred to above;		
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.			
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
	E OF INVENTOR(S)		
	e: DANIEL COHEN		
Signature: _	Citizen of: FRANCE		
Inventor two	D: _ILYA CHUMAKOV		
Signature: _	Signature:Citizen of: _FRANCE		
Inventor three: MARTA BLUMENFELD			
Signature: _	Citizen of: _FRANCE		
Inventor for	ır: SANOBER SHAIKH		
Signature: _	Citizen of: _GREAT BRITAIN		
✓ Addit	ional inventors or a legal representative are being named ononeadditional form(s) attached hereto.		

PTO/SB/01A (09-04)
Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
I/we have r amendmen	I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
EUL NAM	E OF INVENTOR(S)	
	e: MARTA PALICIO-BARRON	
	Signature:Citizen of: FRANCE	
Inventor six	:: _HADLABDERRAHIM	
Signature:	Citizen of: FRANCE	
	ven: PASCALE GREL	
Signature:	Citizen of: FRANCE	
Inventor eig	pht:	
Signature:	Citizen of:	
Addit	ional inventors or a legal representative are being named onadditional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;	
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
	E OF INVENTOR(S)	
Inventor one: DANIEL COHEN		
Signature:Citizen of: _FRANCE		
Inventor two	Inventor two: <u>ILYA CHUMAKOV</u>	
Signature:	Citizen of: FRANCE	
Inventor thr	ee: MARTA BLUMENFELD	
Signature:	Citizen of: FRANCE	
Inventor for	Ir: SANOBER SHAIKH	
Signature: _	Citizen of: GREAT BRITAIN	
✓ Addit		
⊢∟≛J Addit	ional inventors or a legal representative are being named on one additional form(s) attached hereto.	

16/519336 (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
ļ	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
material to became av	Medge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which ailable between the filing date of the prior application and the national or PCT International filing date of the n-in-part application.		
to be true, a punishable	All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	E OF INVENTOR(S)		
Inventor five: MARTA PALICIO-BARRON			
Signature:	Citizen of: FRANCE		
Inventor six	:: HADI ABDERRAHIM		
Signature:	Citizen of: FRANCE		
Pinventor se	ven: PASCALE GREL		
Signature:	Citizen of: FRANCE		
Inventor eig	jht:		
Signature:	Citizen of:		
Addi	ional inventors or a legal representative are being named onadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY Filing Date December 22, 2004	Under the Paperwork Reduction Act of 1995, no persons are requi	Application Number	10/519,336
	POWER OF ATTORNEY	Filing Date	December 22, 2004

and CORRESPONDENCE ADDRESS **INDICATION FORM**

Application Number	10/519,336	
Filing Date	December 22, 2004	
First Named Inventor	Daniel Cohen	
Title	Use of PP2A Phosphatase	
Art Unit		
Examiner Name		
Attorney Docket Number	G-194US04PCT	

	Attorney Bocket Itali	G-194030	AF C I	
I hereby appoint:				
Practitioners associated with the Customer Number: OR	2355	57)		
Practitioner(s) named below:				
Name	,	Registration N	lumber	
· · · · · · · · · · · · · · · · · · ·				
as my/our attorney(s) or agent(s) to prosecute the application in Trademark Office connected therewith.	lentified above, and to tra	ansact all business i	n the United States Patent and	t
Please recognize or change the correspondence address for the The address associated with the above-mentioned Cu		ation to:		
OR		 		•
The address associated with Customer Number:				
OR Firm or				
Individual Name				
Address				
Address	Ctata		Zip	
City	State			
Telephone	Fax			
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)				
SIGNATURE of Applicant or Assignee of Record				
Name Daniel Cohen				
Signature				
Date February 18, 7005		Telephone		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.				
*Total of forms are submitted.				

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

ed to respond to a collection of into	mation unless it displays a valid OMB control number.
Application Number	10/519.336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

I hereby ap	point:				
	titioners associated v	with the Customer Number:	23557	>	
OR		•		-	
Prac	titioner(s) named bel	low:		·	
		Name		Registration Number	
-					
-			-	· · · · · · · · · · · · · · · · · · ·	
			 		
	attorney(s) or agent(s Office connected the	s) to prosecute the application identifice erewith.	ed above, and to trans	act all business in the United State	s Patent and
Please reco	ognize or change the	correspondence address for the above	ve-identified applicatio	on to:	
اا لىكا	ne address associate	ed with the above-mentioned Custome	er Number:		
OR		*			
_ т	The address associated with Customer Number:				
OR					
	Firm or Individual Name				
Addr	ess				
Addr	ess				
City			State	Zip	
Cour			Fax		
I am the:	phone		rax		
	oplicant/Inventor.				
		the entire interest. See 37 CFR 3.71. FR 3.73(b) is enclosed. (Form PTO/Si	B/96)		
		SIGNATURE of Applica	ant or Assignee of R	Record	
Name	Ilya Chumakov	My			
Signature	Signature // // // // // // // // // // // // //				
Date	18th reb	.2005		Telephone	
NOTE: Signatories forms if more	atures of all the inventor than one signature is r	rs or assignees of record of the entire intere required, see below*.	st or their representative	(s) are required. Submit multiple	· · · · · · · · · · · · · · · · · · ·
-Tota	al of	forms are submitted.			

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it distances and CASS.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

	ormation unless it displays a valid OMB control number.
Application Number	10/519.336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

	Attorney Docket Number	G-194USU4PC1	
I hereby appoint:			
Practitioners associated with the Customer Number: OR	23557		
Practitioner(s) named below:			
Name	F	Registration Number	
as my/our attorney(s) or agent(s) to prosecute the application in Trademark Office connected therewith.	dentified above, and to transact a	all business in the United States Patent and	
Please recognize or change the correspondence address for the The address associated with the above-mentioned Cu	• •	;	
OR			
The address associated with Customer Number:			
OR			
Firm or Individual Name			
Address			
Address			
City	State	Zip	
Country			
Telephone	Fax		
l am the: ✓ Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			
SIGNATURE of Applicant or Assignee of Record			
Name Hadi Abderrahim			
Signature Moder and the			
Date 2 410 - 105	Те	lephone	
NOTE: Signatures of all the inventors or assignees of record of the entire forms if more than one signature is required, see below.	e interest or their representative(s) are	e required. Submit multiple	
*Total of forms are submitted.			

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	•
Attorney Docket Number	G-194US04PCT

1 harabir appoints				
I hereby appoint:	 -			· ·
✓ Practitioners as	sociated with the Customer Number:	23557		
OR ·				
Practitioner(s) r	named below:			
	Name	<u> </u>	Registration N	lumber
			,	
as my/our attorney(s) Trademark Office con	or agent(s) to prosecute the application ident	ified above, and to tran	nsact all business ir	n the United States Patent and
•				
	nange the correspondence address for the at	pove-identified applicati	tion to:	
The address	associated with the above-mentioned Custon	mer Number:		
OR			1	
	·			
The address associated with Customer Number:				
.OR				
Firm or Individual	Name			
Address	Traine .		0	
Address				
City		State		Zip
Country				
Telephone		Fax		
I am the: Applicant/Inv				
Statement un	ecord of the entire interest. See 37 CFR 3.71 oder 37 CFR 3.73(b) is enclosed. (Form PTO)	/SB/96)		
	SIGNATURE of Appl	icant or Assignee of I	Record	
Name Marta Blu	menfeld			
Signature	(norse of			
Date Les	ruary 28th 200	<u> </u>	Telephone	
	ne inventors or assignees of record of the entire integrature is required, see below*.	erest or their representative	re(s) are required. Sub	omit multiple
*Total of	forms are submitted.	•		

Rec'd PCT/PTO 25 JUL 20055 794 A. 10/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control num

POWER OF ATTORNEY and **CORRESPONDENCE ADDRESS** INDICATION FORM

Application Number	10/519.336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

	· · · · · · · · · · · · · · · · · · ·			
I hereby appoint:				
Practitioners associated OR	with the Customer Number:	23557	>	
			•	
Practitioner(s) named be	elow:		•	
	Name		Registration	Number .
				0.1
		*		
		-u		
			····	
as my/our attorney(s) or agent Trademark Office connected th	s) to prosecute the application identified erewith.	above, and to trans	sact all business	in the United States Patent and
Please recognize or change the	e correspondence address for the above-	identified application	on to	
			J., 10.	
ine address associat	ed with the above-mentioned Customer I	Number:		
OR				
The address associated with Customer Number:				
OR				,
Firm or Individual Name				
Address				
Address	 		31.00	
City	·	State	-	Zip
Country			·· -	
Telephone		Fax		
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)				
Statement under 37 C		*		
	SIGNATURE of Applicant	t or Assignee of R	Record ·	
Name Sanober Shaikh		ų.		
Signature 5. Shuth.				
Date 10/03/65	5		Telephone /	33(O) 143265986
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.				
*Total of	forms are submitted.			

10/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name .	,
Attorney Docket Number	G-194US04PCT

I hereby appoint:									
✓ Practiti	Practitioners associated with the Customer Number:								
OR					⊣				
Practitioner(s) named below:									
	Name			Registration Number					
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.									
Please recognize or change the correspondence address for the above-identified application to:									
The address associated with the above-mentioned Customer Number:									
OR .									
The address associated with Customer Number:									
OR									
	im or ndividual Name								
Addres	is		, , , , , , , , , , , , , , , , , , ,						
Addres	SS			0					
City			State		Zip				
Country			T =						
Telephone			Fax						
am the:	licant/Inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)									
SIGNATURE of Applicant or Assignee of Record									
Name Marta Palicio-Barron									
Signature Hacta Palicio									
Date	20thebridy			Telephone +	33370742346				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.									
*Total of forms are submitted.									

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

ired to respond to a collection of fill	of the state of th			
Application Number	10/519.336			
Filing Date	December 22, 2004			
First Named Inventor	Daniel Cohen			
Title	Use of PP2A Phosphatase			
Art Unit				
Examiner Name				
Attorney Docket Number	G-194US04PCT			

I hereby appoint:									
√ Prac	Practitioners associated with the Customer Number:								
OR									
Practitioner(s) named below:									
	Name			Registration Number					
	Hame								
					*				
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.									
Please rec	ognize or change the	correspondence address for the above	-identified annlication	on to					
				on to.					
TI L	he address associate	ed with the above-mentioned Customer	Number:						
OR									
l T	he address associate	ed with Customer Number:							
OR									
	Firm or Individual Name								
Addı	ress								
Addı	ress								
City			State	Zip					
Country									
Tele	phone		Fax						
l am the: ✓ Applicant/Inventor.									
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)									
SIGNATURE of Applicant or Assignee of Record									
Name	Pascale Grel								
Signature	40								
Date	18-2-	25		Telephone 01-60 - 79.	-66-14				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.									
*Total of forms are submitted.									